The Non-Rhabdomyosarcoma drugs in development market research report provides comprehensive information on the therapeutics under development for Non-Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Non-Rhabdomyosarcoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Non-Rhabdomyosarcoma and features dormant and discontinued products.
GlobalData tracks 112 drugs in development for Non-Rhabdomyosarcoma by 86 companies/universities/institutes. The top development phase for Non-Rhabdomyosarcoma is phase ii with 60 drugs in that stage. The Non-Rhabdomyosarcoma pipeline has 106 drugs in development by companies and six by universities/ institutes. Some of the companies in the Non-Rhabdomyosarcoma pipeline products market are: AstraZeneca, Chia Tai Tianqing Pharmaceutical Group and Pfizer.
The key targets in the Non-Rhabdomyosarcoma pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22), and Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22).
The key mechanisms of action in the Non-Rhabdomyosarcoma pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with 12 drugs in Phase II. The Non-Rhabdomyosarcoma pipeline products include 16 routes of administration with the top ROA being Intravenous and 13 key molecule types in the Non-Rhabdomyosarcoma pipeline products market including Small Molecule, and Monoclonal Antibody.
Non-Rhabdomyosarcoma overview
Non-rhabdomyosarcoma refers to a group of cancers that are distinct from rhabdomyosarcoma, a type of soft tissue cancer that arises from skeletal muscle cells. Non-rhabdomyosarcoma includes various types of soft tissue sarcomas that originate in tissues such as nerves, blood vessels, fat, and connective tissues. These sarcomas can occur in different parts of the body, and their characteristics and treatment approaches vary. Common subtypes include liposarcoma, leiomyosarcoma, and synovial sarcoma. Diagnosis involves imaging, biopsy, and molecular testing. Treatment typically involves surgery, radiation therapy, and sometimes chemotherapy, depending on the specific subtype and stage of the non-rhabdomyosarcoma.
For a complete picture of Non-Rhabdomyosarcoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
